Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Immunocore Holdings (IMCR) Interest Expenses (2023 - 2025)

Historic Interest Expenses for Immunocore Holdings (IMCR) over the last 5 years, with Q3 2025 value amounting to $3.0 million.

  • Immunocore Holdings' Interest Expenses fell 2906.76% to $3.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.2 million, marking a year-over-year increase of 2314.91%. This contributed to the annual value of $18.8 million for FY2024, which is 26561.89% up from last year.
  • According to the latest figures from Q3 2025, Immunocore Holdings' Interest Expenses is $3.0 million, which was down 2906.76% from $3.0 million recorded in Q2 2025.
  • In the past 5 years, Immunocore Holdings' Interest Expenses registered a high of $10.4 million during Q4 2022, and its lowest value of -$2.6 million during Q1 2021.
  • Its 5-year average for Interest Expenses is $2.2 million, with a median of $2.2 million in 2023.
  • In the last 5 years, Immunocore Holdings' Interest Expenses surged by 67340.66% in 2022 and then plummeted by 8745.69% in 2023.
  • Over the past 5 years, Immunocore Holdings' Interest Expenses (Quarter) stood at -$1.8 million in 2021, then skyrocketed by 673.41% to $10.4 million in 2022, then crashed by 87.46% to $1.3 million in 2023, then surged by 437.66% to $7.0 million in 2024, then plummeted by 56.76% to $3.0 million in 2025.
  • Its last three reported values are $3.0 million in Q3 2025, $3.0 million for Q2 2025, and $3.0 million during Q1 2025.